Zydus Cadila gets USFDA nod for Ranolazine Extended-Release tablets to treat chronic angina
The company has received approval for Ranolazine Extended-Release tablets from the United States Food and Drug Administration (USFDA) to market the product in the strengths of 500 mg and 1,000 mg, Zydus Cadila said in a statement.
New Delhi: Drug firm Zydus Cadila on Wednesday said it has received final approval from the US health regulator to market generic Ranolazine Extended-Release tablets used for the treatment of chronic angina.
The company has received approval from the United States Food and Drug Administration (USFDA) to market the product in the strengths of 500 mg and 1,000 mg, Zydus Cadila said in a statement.
The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control, it added.
The tablets will be manufactured at the group’s formulations manufacturing facility at Baddi, Zydus Cadila said.
The group now has 271 approvals and has so far filed over 360 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here